Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Aromatase Inhibitor
42%
Metastatic Breast Cancer
40%
Neoplasm
30%
Solid Malignant Neoplasm
23%
Hormone Receptor
23%
Paclitaxel
21%
Triple Negative Breast Cancer
21%
Tolerability
18%
Disease
18%
Tamoxifen
18%
Chemotherapy
17%
Adverse Event
15%
Arthralgia
14%
Progression Free Survival
13%
Clinical Trial
13%
Cyclophosphamide
12%
Biological Marker
12%
Exemestane
12%
Arthritis
11%
Doxorubicin
11%
Sunitinib
11%
Malignant Neoplasm
11%
Inflammatory Breast Cancer
10%
Pancreas Adenocarcinoma
10%
Diethylstilbestrol
10%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
10%
Thrombotic Thrombocytopenic Purpura
10%
Lobular Carcinoma
10%
Eribulin
10%
Oxylipin
10%
Programmed Death 1 Ligand 1
10%
Fulvestrant
10%
Irinotecan
10%
Musculoskeletal Disease
10%
Tucatinib
10%
Antiangiogenic Therapy
10%
Placebo
10%
Granulocyte Colony Stimulating Factor
10%
Aeg 35156
10%
Etoposide
10%
Bavituximab
10%
Pharmacokinetics
10%
Pathophysiology
10%
Tumor Marker
10%
Abemaciclib
10%
Metastatic Melanoma
10%
Sulindac
10%
Carcinomatous Meningitis
10%
Naphthalimide Derivative
10%
Medicine and Dentistry
Breast Cancer
75%
Malignant Neoplasm
43%
Aromatase Inhibitor
36%
Symptom
34%
Postmenopause
26%
Symptom Management
26%
Neoplasm
25%
Biological Marker
24%
Breast Density
21%
Randomized Controlled Trial
21%
Arthralgia
21%
Survivorship in Cancer Care
17%
Magnetic Resonance Imaging
16%
Quality of Life
15%
Metastatic Breast Cancer
15%
Solid Malignant Neoplasm
15%
Hormone Receptor
15%
Breast Cancer Prevention
11%
Cancer Therapy
11%
Sulindac
10%
Diethylstilbestrol
10%
Antiangiogenic Therapy
10%
Pancreas Adenocarcinoma
10%
Shear Wave Elastography
10%
Oxylipin
10%
Metabolic Syndrome
10%
Aromatase
10%
Thrombotic Thrombocytopenic Purpura
10%
Acidosis
10%
Obesity
10%
Health Service
10%
Western Ontario and McMaster Universities Osteoarthritis Index
10%
Bavituximab
10%
Chemotherapy
10%
Glycon
10%
Distress Syndrome
10%
Aeg 35156
10%
Abemaciclib
10%
Pathophysiology
10%
Tucatinib
10%
Lobular Carcinoma
10%
Meningeal Carcinomatosis
10%
Carbonate Dehydratase IX
10%
Transcranial Magnetic Stimulation
10%
Nonsteroid Antiinflammatory Agent
10%
Supportive Care
10%
Hormone Therapy
7%
Response Evaluation Criteria in Solid Tumors
7%
Arm
6%
Hot Flush
6%
Keyphrases
Sulindac
21%
Quality of Life
21%
Aromatase Inhibitors
21%
Breast Density
21%
Aromatase Inhibitor-induced Arthralgia
21%
Cancer Survivors
21%
Stiffness
16%
Postmenopausal Women
15%
Caregivers
13%
WOMAC
12%
Informal Caregivers
12%
Breast Cancer Patients
11%
Breast Cancer Prevention
11%
Randomized Controlled Trial
11%
Adiposity
10%
Intervention Feasibility
10%
Invasive Lobular Carcinoma
10%
Immunochemotherapy
10%
Molecular Characteristics
10%
Somatic Aberrations
10%
Rare Cancer
10%
Metastatic Pancreatic Adenocarcinoma
10%
Endocrine Therapy
10%
Non-selective NSAIDs
10%
Diffuse Tensor Imaging
10%
AcidoCEST
10%
Metformin
10%
Eribulin
10%
Sunitinib Malate
10%
Oxylipins
10%
Tumor
10%
Estrogen Receptor-positive Metastatic Breast Cancer
10%
Correction Dose
10%
Health Care Services
10%
Treatment Considerations
10%
Musculoskeletal Symptoms
10%
Metastatic Triple-negative Breast Cancer
10%
CDK7 Inhibitor
10%
Urogenital Symptoms
10%
Metabolic Syndrome Components
10%
Magnetic Resonance Imaging
10%
AEG35156
10%
Extended Interval Dosing
10%
BAY 94-9027
10%
BNT162b2 Vaccine
10%
Women with Breast Cancer
10%
Xiap
10%
Tucatinib
10%
Programmed Death-ligand 1 (PD-L1)
10%
Treatment Options
10%
